BTIG Research Boosts Aura Biosciences (NASDAQ:AURA) Price Target to $24.00

Aura Biosciences (NASDAQ:AURA) had its price objective hoisted by BTIG Research from $21.00 to $24.00 in a research report sent to investors on Friday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

AURA has been the topic of a number of other research reports. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. JMP Securities boosted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, September 13th. Finally, HC Wainwright boosted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Down 0.8 %

NASDAQ:AURA opened at $11.65 on Friday. The company has a market cap of $577.18 million, a P/E ratio of -6.26 and a beta of 0.37. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.38. The company’s 50-day moving average price is $8.74 and its 200-day moving average price is $8.10.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. On average, analysts expect that Aura Biosciences will post -1.7 earnings per share for the current year.

Insider Activity

In other news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the transaction, the insider now directly owns 329,847 shares in the company, valued at $3,971,357.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 57,506 shares of company stock valued at $675,952. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Levin Capital Strategies L.P. lifted its position in Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after buying an additional 41,711 shares during the last quarter. American International Group Inc. lifted its position in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares during the last quarter. Long Focus Capital Management LLC increased its stake in Aura Biosciences by 113.4% during the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Aura Biosciences during the first quarter worth about $144,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.